Tasigna® has been linked to Atherosclerosis and other serious side effects including Amputation, Stroke, Heart Attack, and Death.
Several recent studies have reported vascular toxicity with nilotinib (Tasigna®) (Table 1). In a retrospective multicenter analysis of 179 patients, 11 patients (6.2%) developed peripheral arterial disease (PAD) involving lower limbs. Most striking was the severity of PAD; eight patients required invasive therapy (angioplasty and stent placement), and four patients required amputation.56
READ MORE at Journal of Clinical Oncology
Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
The medical journal Leukemia published an article revealing a link between Tasigna® and peripheral artery occlusive disease (PAOD). Results of their study showed that people using Tasigna® were more likely to develop PAOD than those using a competing medication.
READ MORE at Leukemia (Scholarly Journal)
Nilotinib (Tasigna®) appears to cause metabolic changes, including an increase in the fasting glucose level. In addition, vascular adverse events, including progressive atherosclerosis with peripheral arterial occlusive disease (AOD) have been reported in nilotinib-treated CML patients.
READ MORE at Blood (Scholarly Journal)